Hypertensive Disorders of Pregnancy: A Critical Concern for Maternal and Fetal Health

Introduction

Hypertensive disorders of pregnancy include gestational hypertension, preeclampsia, and eclampsia. Though Hypertensive Disorders of Pregnancy (HDP) are well-known in modern medicine, there are gaps in the knowledge regarding causes, contributing factors, and early indicators of this family of disorders. According to the Centers for Disease Control, HDP impacts 1 in every 12 to 17 pregnancies, based on NHANES data [1]. At the same time, the rate of HDP increased from approximately 13% in 2017 to 16% in 2019 [2]. HDP is a significant risk factor for adverse maternal and fetal outcomes [3]. Approximately one-third of maternal deaths who died during hospital delivery were documented to have HDP [4]. HDP poses multifaceted challenges to maternal health, elevating the risk of conditions such as preeclampsia and gestational diabetes. Preeclampsia not only endangers maternal well-being but also predisposes individuals to cardiovascular complications postpartum [5]. Moreover, the long-term implications of hypertension extend beyond pregnancy, increasing the susceptibility to chronic conditions like hypertension and cardiovascular disease, [6] underscoring the importance of early intervention and preventive measures. HDP can also lead to maternal complications such as stroke, organ failure, and even death [7] Proper management during pregnancy and follow-up care postpartum are crucial in mitigating the risk of conditions such as preeclampsia [8]. Preeclampsia can affect maternal kidney function, leading to proteinuria and impaired kidney function [9]. In severe cases, pre-eclampsia may lead to kidney failure, necessitating dialysis or kidney transplant [10]. These maternal complications can indirectly impact fetal development by affecting maternal health and well-being.

The ramifications of HDP extend to fetal development, disrupting placental function and compromising fetal growth [11]. Reduced uteroplacental blood flow stemming from hypertensive disorders can lead to Intrauterine Growth Restriction (IUGR), increasing the likelihood of preterm birth and associated neonatal complications [12]. In severe cases of hypertensive disorders, there may be a risk of preterm birth. Preterm birth can lead to a range of complications for the newborn, including respiratory distress syndrome, infections, and long-term developmental issues [13]. HDP increases the risk of placental abruption. Placental abruption can lead to severe bleeding and compromise fetal oxygen supply, potentially resulting in fetal distress, preterm birth, or even fetal death. Reduced blood flow through the placenta due to hypertension can result in fetal distress due to decreased oxygen and nutrients needed for proper development [14] Reduced blood flow can lead to abnormalities in fetal heart rate patterns and may necessitate interventions such as early delivery. There is growing evidence suggesting that exposure to hypertensive disorders in utero may increase the risk of neurodevelopmental issues in the offspring, including cognitive impairments, learning disabilities, and behavioral problems later in life [15] Furthermore, HDP is linked to altered programming of fetal metabolism, potentially predisposing offspring to metabolic syndrome and cardiovascular disease later in life, highlighting the intergenerational impact of maternal health status. Mothers with HDP often have infants born with a higher risk of cardiovascular issues later in life. The increased risk is thought to be due to the adverse effects of intrauterine exposure to hypertension on cardiovascular development.

In my opinion, many of the health consequences HDP could be mitigated with medical nutrition therapy intervention early in pregnancy. Nutrient status and intake have been overlooked as a cornerstone in managing HDP, offering a modifiable avenue for risk reduction intervention and potential prevention strategy. Including a registered dietitian on the care team can be a successful strategy for emphasizing a diet rich in essential nutrients, including potassium, calcium, and magnesium, while assessing vitamin D status holds promise in attenuating hypertension and supporting vascular health. Additionally, advocating for lifestyle modifications, such as regular physical activity and weight management, complements food routine interventions, fostering comprehensive approaches to early blood pressure management during pregnancy. Effective management of HDP necessitates interdisciplinary collaboration, encompassing healthcare professionals from diverse fields. Integrating nutritional counseling within prenatal care frameworks empowers expecting mothers to make informed dietary choices, fostering optimal maternal and fetal outcomes. Furthermore, leveraging technological advancements in remote monitoring and telemedicine facilitates continuous surveillance of blood pressure trends, enabling timely interventions and mitigating the risk of hypertension- related complications. While the pathogenetic pathway is not well understood, we do know that gestational hypertension is typically diagnosed after 20 weeks gestation. Early identification of risk factors and monitoring and managing them are crucial to minimizing their impact on maternal and fetal health. In conclusion, HDP represents a critical concern with profound implications for maternal and fetal health. It is imperative to delve into the intricate relationship between HDP and its consequences, shedding light on the pivotal role of nutrition in mitigating its impact. As a registered dietitian specializing in nutrition during pregnancy, advocating for holistic approaches that prioritize nutrition, lifestyle modifications, and interdisciplinary collaboration emerges as paramount. By addressing the multifaceted challenges of HDP through comprehensive strategies, including medical nutrition therapy, maternal and fetal health can be optimized.

References

• Mochumba F, Shah N (2022) Trends in Racial and Ethnic Disparities in Severe Maternal Morbidity. Am J Obstet Gynecol 226(1): S730-S731.
• Malamati K, Eleni L, Athanasia C, Vasilios K, Stella S (2021) Clinical outcomes of hypertensive disorders in pregnancy in the offspring during perinatal period, childhood, and adolescence. J Hum Hypertens 35(12): 1063-1073.
• Nguyen AH, Hurwitz M, Sullivan SA, Saad A, Kennedy JLW, et al. (2024) Update on sex specific risk factors in cardiovascular disease. Front Cardiovasc Med 11.
• Ford ND, Cox S, Ko JY, Lijing Ouyang, Lisa Romero, et al. (2022) Hypertensive Disorders in Pregnancy and Mortality at Delivery Hospitalization-United States, 2017–2019 Morb Mortal Wkly Rep 71(17): 585-591.
• Wu R, Wang T, Gu R, Dexiu Xing, Changxiang Ye, et al. (2020) Hypertensive Disorders of Pregnancy and Risk of Cardiovascular Disease-Related Morbidity and Mortality: A Systematic Review and Meta-Analysis. Cardiology 145(10): 633-647.
• Stuart JJ, Tanz LJ, Missmer SA, et al. (2018) Hypertensive disorders of pregnancy and maternal cardiovascular disease risk factor development: An observational cohort study. Ann Intern Med 169(4): 224-232.
• Subki AH, Algethami MR, Baabdullah WM, Majed N Alnefaie, Mashael A Alzanbagi, et al. (2018) Prevalence, Risk Factors, and Fetal and Maternal Outcomes of Hypertensive Disorders of Pregnancy: A Retrospective Study in Western Saudi Arabia. Oman Med J 33(5): 409-415.
• Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S (2020) Preeclampsia-Pathophysiology and Clinical Presentations: JACC State-of-the-Art Review. J Am Coll Cardiol 76(14): 1690-1702.
• Barrett PM, McCarthy FP, Evans M, Marius Kublickas, Ivan J Perry, et al. (2020) Hypertensive disorders of pregnancy and the risk of chronic kidney disease: A Swedish registry-based cohort study. PLoS Med 17(8).
• Overton E, Tobes D, Lee A (2022) Preeclampsia diagnosis and management. Best Pr Res Clin Anaesthesiol 36(1): 107-121.
• Joo EH, Kim YR, Kim N, Jung JE, Han SH, et al. (2021) Effect of endogenic and exogenic oxidative stress triggers on adverse pregnancy outcomes: Preeclampsia, fetal growth restriction, gestational diabetes mellitus and preterm birth. Int J Mol Sci 22(18): 10122.
• Di Martino DD, Avagliano L, Ferrazzi E, Federica Fusè, Vittoria Sterpi, et al. (2022) Hypertensive Disorders of Pregnancy and Fetal Growth Restriction: Clinical Characteristics and Placental Lesions and Possible Preventive Nutritional Targets. Nutrients 14(16): 3276.
• Nakamura N, Ushida T, Nakatochi M, Yumiko Kobayashi, Yoshinori Moriyama, et al. (2021) Mortality and neurological outcomes in extremely and very preterm infants born to mothers with hypertensive disorders of pregnancy. Sci Rep 11(1): 1729.
• Naruse K, Shigemi D, Hashiguchi M, Imamura M, Yasunaga H, et al. (2021) Advanced Life Support in Obstetrics (ALSO)-Japan Research Group. Placental abruption in each hypertensive disorders of pregnancy phenotype: a retrospective cohort study using a national inpatient database in Japan. Hypertens Res 44(2): 232-238.
• Huang C, Wei K, Lee PMY, Qin G, Yu Y, et al. (2022) Maternal hypertensive disorder of pregnancy and mortality in offspring from birth to young adulthood: National population-based cohort study. BMJ 379: e072157.